|
Re: FXR and liver transaminase related adverse events
|
5
|
Resverlogix Corp.
|
Oct 03, 2018 11:32AM
|
|
Re: what a humble board looks like ..
|
5
|
Resverlogix Corp.
|
Sep 12, 2016 01:29PM
|
|
Re: ... time lines and yet to come...
|
5
|
Resverlogix Corp.
|
Aug 16, 2018 04:34PM
|
|
Re: Article
|
5
|
Resverlogix Corp.
|
Oct 25, 2020 06:20PM
|
|
BRD4 inhibition and FXR activation, individually beneficial in cholestasis, are antagonistic in combination
|
5
|
Resverlogix Corp.
|
Jan 06, 2021 11:25AM
|
|
Re: Resverlogix Announces Filing of Quarterly Financial Statements and Management's Discussion & Analysis
|
5
|
Resverlogix Corp.
|
Sep 13, 2017 10:25PM
|
|
Re: RVX-208 vs. CETP inhibitors
|
5
|
Resverlogix Corp.
|
Aug 19, 2015 12:34PM
|
|
Re: Kidney data rocks!
|
5
|
Resverlogix Corp.
|
Nov 16, 2019 02:37PM
|
|
Re: Resverlogix Announces Corporate Update Conference Call ... Bear
|
5
|
Resverlogix Corp.
|
Jun 07, 2020 05:45PM
|
|
Re: Reaching 250 MACE
|
5
|
Resverlogix Corp.
|
Apr 23, 2019 11:09AM
|
|
Re: New paper on interplay/synergy of BET inhibitors and PD-L1 inhibition
|
5
|
Zenith Epigenetics
|
Mar 03, 2017 01:10PM
|
|
Re: Dr Sweeney
|
5
|
Resverlogix Corp.
|
Jun 21, 2016 11:20PM
|
|
Re: The thread has been killed
|
5
|
Resverlogix Corp.
|
Jun 12, 2019 04:23PM
|
|
Resverlogix Reschedules Update Webcast and Conference Call: Now February 4th 10AM MT
|
5
|
Resverlogix Corp.
|
Jan 27, 2021 05:44PM
|
|
Zenith June 30th Special Meeting Information Circular
|
5
|
Resverlogix Corp.
|
Jun 09, 2015 11:34AM
|
|
Please keep post respectful
|
5
|
Resverlogix Corp.
|
Jan 22, 2021 04:18PM
|
|
Re: BIO International 2018
|
5
|
Zenith Epigenetics
|
May 27, 2018 03:11PM
|
|
Cytokine storm hypothesis takes a hit with the latest IL-6 targeted therapies
|
5
|
Resverlogix Corp.
|
Apr 27, 2020 12:42PM
|
|
Re: Renal and Fabry trial listings updated on ClinicalTrials.gov
|
5
|
Resverlogix Corp.
|
Apr 21, 2018 12:05PM
|
|
Re: NEW BLOG POST
|
5
|
Resverlogix Corp.
|
Jun 25, 2015 02:14PM
|
